Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

الاستراتيجية الوطنية للتحصين للأعوام ٢٠١٧-٢٠٢٢


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    123
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA01 SIMVASTATIN NORMON G Simvastatin - 10mg 10mg Tablet, film coated 264,737 L.L
R03DC03 LUKAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 802,274 L.L
C10AA01 STAVINE G Simvastatin - 10mg 10mg Tablet 207,336 L.L
R03DC03 MONTELUKAST ARROW LAB G Montelukast (sodium) - 10mg 10mg Tablet, film coated 978,317 L.L
C10AA01 VASCOR G Simvastatin - 10mg 10mg Tablet, scored 284,127 L.L
R03DC03 MONTELUKAST-SANDOZ G Montelukast (sodium) - 10mg 10mg Tablet, film coated 1,136,296 L.L
M03BX08 JAMP-CYCLOBENZAPRINE G Cyclobenzaprine HCl - 10mg 10mg Tablet 4,031,528 L.L
R03DC03 MOTRINEX G Montelukast - 10mg 10mg Tablet, film coated 802,274 L.L
R03DC03 RELIEFAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 844,701 L.L
C01DA08 ISDN G Isosorbide dinitrate - 10mg 10mg Tablet 311,771 L.L
R03DC03 ROMILAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 228,453 L.L
C01DA08 ISODEX G Isosorbide dinitrate - 10mg 10mg Tablet 138,224 L.L
R03DC03 UNICAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 802,274 L.L
C09AA03 ZESTRIL B Lisinopril (dihydrate) - 10mg 10mg Tablet 592,635 L.L
C09AA04 COVERSYL ARGININE B Perindopril arginine - 10mg 10mg Tablet, film coated 452,875 L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule 110,200,672 L.L
N06DX01 EBIXA B Memantine HCl - 10mg 10mg Tablet, film coated 2,143,429 L.L
L04AX04 ERVALI G Lenalidomide - 10mg 10mg Capsule, hard 71,493,520 L.L
N06DX01 EXENTA G Memantine HCl - 10mg 10mg Tablet, film coated 1,057,156 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 10mg 10mg Tablet, scored 431,373 L.L
L04AX04 LEDOBOOK 10 G Lenalidomide - 10mg 10mg Capsule 62,230,245 L.L
N06DX01 MEMANTINE ARROW LAB G Memantine HCl - 10mg 10mg Tablet, film coated, scored 1,404,315 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 10mg 10mg Tablet, scored 431,373 L.L
L04AX04 LENALIDOMIDE ARROW G Lenalidomide - 10mg 10mg Capsule 26,651,802 L.L
N06DX01 MEMANTINE BIOGARAN G Memantine HCl - 10mg 10mg Tablet, coated, scored 2,444,450 L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 10mg 10mg Capsule 72,248,183 L.L
N06DX01 MEMORA G Memantine HCl - 10mg 10mg Tablet, film coated 849,820 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 10mg 10mg Capsule, hard 75,120,146 L.L
L04AX04 LENALIDOMIDE STRAGEN G Lenalidomide - 10mg 10mg Capsule 33,314,752 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard 14,449,637 L.L
    ...
    123
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025